Use of growth factors in the repair of bone;Utilisation de facteurs de croissance pour la réparation osseuse

Pathologie Biologie

Volumn 53, Issue 3, 2005, Pages 131-141

  Degat, M C ^a   Ferreira, E ^a   Logeart Avramoglou, D ^a  

^a Paris university   (France)

Author keywords

BMP; Carrier; Drug delivery systems; Gene therapy; Growth factors

Indexed keywords

ADENOVIRUS VECTOR; BIOMATERIAL; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 12; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 8; DORSALINE; GROWTH DIFFERENTIATION FACTOR 1; GROWTH DIFFERENTIATION FACTOR 10; GROWTH DIFFERENTIATION FACTOR 3; GROWTH DIFFERENTIATION FACTOR 5; GROWTH DIFFERENTIATION FACTOR 6; GROWTH DIFFERENTIATION FACTOR 9; GROWTH FACTOR; INHIBINE ALPHA; INHIBINE BETA A; INHIBINE BETA B; INHIBINE BETA C; OSTEOGENIC PROTEIN 1; OSTEOGENIN; PARVOVIRUS VECTOR; POLYMER; RETROVIRUS VECTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG;

ARTICLE; BONE CONDUCTION; BONE REMODELING; CELL TRANSPLANTATION; ELECTROPORATION; EX VIVO STUDY; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; IN VIVO STUDY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN INDUCTION; PROTEIN SECRETION; VIRAL GENE DELIVERY SYSTEM;

EID: 15744390548     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2004.03.004     Document Type: Article

References (70)

1. Damien C.J., Parsons J.R. Bone graft and bone graft substitutes: a review of current technology and applications. J Appl Biomater. 2:(3):1991;187-208
2. Duguy N., Petite H., Arnaud E. Biomaterials and osseous regeneration]. Ann Chir Plast Esthet. 45:(3):2000;364-376
3. Rey C. Calcium phosphate biomaterials and bone mineral. Differences in composition, structures and properties. Biomaterials. 11:1990;13-15
4. Lane J.M., Tomin E., Bostrom M.P. Biosynthetic bone grafting. Clin Orthop. (367 Suppl):1999;S107-S117
5. Kingsley D.M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 8:(2):1994;133-146
6. Wozney J.M. The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult. Eur J Oral Sci. 106:(Suppl 1):1998;160-166
7. Zhu H., Kavsak P., Abdollah S., Wrana J.L., Thomsen G.H. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature. 400:(6745):1999;687-693
8. Lind M., Schumacker B., Soballe K., Keller J., Melsen F., Bunger C. Transforming growth factor-beta enhances fracture healing in rabbit tibiae. Acta Orthop Scand. 64:(5):1993;553-556
9. Nielsen H.M., Andreassen T.T., Ledet T., Oxlund H. Local injection of TGF-beta increases the strength of tibial fractures in the rat. Acta Orthop Scand. 65:(1):1994;37-41
10. Wozney J.M., Rosen V., Byrne M., Celeste A.J., Moutsatsos I., Wang E.A. Growth factors influencing bone development. J Cell Sci Suppl. 13:1990;149-156
11. Riley E.H., Lane J.M., Urist M.R., Lyons K.M., Lieberman J.R. Bone morphogenetic protein-2: biology and applications. Clin Orthop. (324):1996;39-46
12. Cook S.D., Baffes G.C., Wolfe M.W., Sampath T.K., Rueger D.C., Whitecloud T.S. 3rd. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg Am. 76:(6):1994;827-838
13. Cho T.J., Gerstenfeld L.C., Einhorn T.A. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res. 17:(3):2002;513-520
14. Wozney J.M., Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop. (346):1998;26-37
15. Urist M.R., Iwata H., Ceccotti P.L., Dorfman R.L., Boyd S.D., McDowell R.M., et al. Bone morphogenesis in implants of insoluble bone gelatin. Proc Natl Acad Sci U S A. 70:(12):1973;3511-3515
16. Urist M.R., Mikulski A., Lietze A. Solubilized and insolubilized bone morphogenetic protein. Proc Natl Acad Sci U S A. 76:(4):1979;1828-1832
17. Hollinger J.O., Uludag H., Winn S.R. Sustained release emphasizing recombinant human bone morphogenetic protein-2. Adv Drug Deliv Rev. 31:(3):1998;303-318
18. Kirker-Head C.A. Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev. 43:(1):2000;65-92
19. Li R.H., Wozney J.M. Delivering on the promise of bone morphogenetic proteins. Trends Biotechnol. 19:(7):2001;255-265
20. McKay B., Sandhu H.S. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine. 27:(16 Suppl 1):2002;S66-S85
21. Nakamura T., Hara Y., Tagawa M., Tamura M., Yuge T., Fukuda H., et al. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture. J Bone Miner Res. 13:(6):1998;942-949
22. Radomsky M.L., Aufdemorte T.B., Swain L.D., Fox W.C., Spiro R.C., Poser J.W. Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J Orthop Res. 17:(4):1999;607-614
23. Raschke M.J., Bail H., Windhagen H.J., Kolbeck S.F., Weiler A., Raun K., et al. Recombinant growth hormone accelerates bone regenerate consolidation in distraction osteogenesis. Bone. 24:(2):1999;81-88
24. Schmidmaier G., Wildemann B., Heeger J., Gabelein T., Flyvbjerg A., Bail H.J., et al. Improvement of fracture healing by systemic administration of growth hormone and local application of insulin-like growth factor-1 and transforming growth factor-beta1. Bone. 31:(1):2002;165-172
25. Sandhu H.S., Khan S.N. Animal models for preclinical assessment of bone morphogenetic proteins in the spine. Spine. 27:(16 Suppl 1):2002;S32-S38
26. Hollinger J.O., Leong K. Poly(alpha-hydroxy acids): carriers for bone morphogenetic proteins. Biomaterials. 17:(2):1996;187-194
27. Schmitt J.M., Hwang K., Winn S.R., Hollinger J.O. Bone morphogenetic proteins: an update on basic biology and clinical relevance. J Orthop Res. 17:(2):1999;269-278
28. Winn S.R., Uludag H., Hollinger J.O. Carrier systems for bone morphogenetic proteins. Clin Orthop. (367 Suppl):1999;S95-S106
29. Uludag H., D'Augusta D., Palmer R., Timony G., Wozney J. Characterization of rhBMP-2 pharmacokinetics implanted with biomaterial carriers in the rat ectopic model. J Biomed Mater Res. 46:(2):1999;193-202
30. Tsuruga E., Takita H., Itoh H., Wakisaka Y., Kuboki Y. Pore size of porous hydroxyapatite as the cell-substratum controls BMP- induced osteogenesis. J Biochem (Tokyo). 121:(2):1997;317-324
31. Klein C.P., Driessen A.A., de Groot K., van den Hooff A. Biodegradation behavior of various calcium phosphate materials in bone tissue. J Biomed Mater Res. 17:(5):1983;769-784
32. Urist M.R., Nilsson O., Rasmussen J., Hirota W., Lovell T., Schmalzreid T., et al. Bone regeneration under the influence of a bone morphogenetic protein (BMP) beta tricalcium phosphate (TCP) composite in skull trephine defects in dogs. Clin Orthop. (214):1987;295-304
33. Alam M.I., Asahina I., Ohmamiuda K., Takahashi K., Yokota S., Enomoto S. Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2. Biomaterials. 22:(12):2001;1643-1651
34. Johnson E.E., Urist M.R., Finerman G.A. Resistant nonunions and partial or complete segmental defects of long bones. Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. Clin Orthop. (277):1992;229-237
35. Friess W., Uludag H., Foskett S., Biron R., Sargeant C. Characterization of absorbable collagen sponges as rhBMP-2 carriers. Int J Pharm. 187:(1):1999;91-99
36. Boyne P.J. Animal studies of application of rhBMP-2 in maxillofacial reconstruction. Bone. 19:(1 Suppl):1996;83S-92S
37. Yudell R.M., Block M.S. Bone gap healing in the dog using recombinant human bone morphogenetic protein-2. J Oral Maxillofac Surg. 58:(7):2000;761-766
38. Riedel G.E., Valentin-Opran A. Clinical evaluation of rhBMP-2/ACS in orthopaedic trauma: a progress report. Orthopedics. 22:(7):1999;663-665
39. Govender S., Csimma C., Genant H., Valentin-Opran A. Recombinant Human Bone Morphogenetic Protein-2 for treatment of open tibial fracture. The Journal of Bone and Joint Surgery. 84-A:(12):2002;2123-2134
40. Boden S.D., Kang J., Sandhu H., Heller J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine. 27:(23):2002;2662-2673
41. Kim H.D., Valentini R.F. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. J Biomed Mater Res. 59:(3):2002;573-584
42. Agrawal C.M., Best J., Heckman J.D., Boyan B.D. Protein release kinetics of a biodegradable implant for fracture non-unions. Biomaterials. 16:(16):1995;1255-1260
43. Yokota S., Sonohara S., Yoshida M., Murai M., Shimokawa S., Fujimoto R., et al. A new recombinant human bone morphogenetic protein-2 carrier for bone regeneration. Int J Pharm. 223:(1-2):2001;69-79
44. Kokubo S., Fujimoto R., Yokota S., Fukushima S., Nozaki K., Takahashi K., et al. Bone regeneration by recombinant human bone morphogenetic protein-2 and a novel biodegradable carrier in a rabbit ulnar defect model. Biomaterials. 24:(9):2003;1643-1651
45. Murakami N., Saito N., Takahashi J., Ota H., Horiuchi H., Nawata M., et al. Repair of a proximal femoral bone defect in dogs using a porous surfaced prosthesis in combination with recombinant BMP-2 and a synthetic polymer carrier. Biomaterials. 24:(13):2003;2153-2159
46. Winn S.R., Hu Y., Sfeir C., Hollinger J.O. Gene therapy approaches for modulating bone regeneration. Adv Drug Deliv Rev. 42:(1-2):2000;121-138
47. Alden T.D., Pittman D.D., Beres E.J., Hankins G.R., Kallmes D.F., Wisotsky B.M., et al. Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy. J Neurosurg. 90:(1 Suppl):1999;109-114
48. Baltzer A.W., Lattermann C., Whalen J.D., Wooley P., Weiss K., Grimm M., et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther. 7:(9):2000;734-739
49. Mason J.M., Grande D.A., Barcia M., Grant R., Pergolizzi R.G., Breitbart A.S. Expression of human bone morphogenic protein 7 in primary rabbit periosteal cells: potential utility in gene therapy for osteochondral repair. Gene Ther. 5:(8):1998;1098-1104
50. Lieberman J.R., Le L.Q., Wu L., Finerman G.A., Berk A., Witte O.N., et al. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res. 16:(3):1998;330-339
51. Levy R.J., Goldstein S.A., Bonadio J. Gene therapy for tissue repair and regeneration. Adv Drug Deliv Rev. 33:(1-2):1998;53-69
52. Laurencin C.T., Attawia M.A., Lu L.Q., Borden M.D., Lu H.H., Gorum W.J., et al. Poly(lactide-co-glycolide)/hydroxyapatite delivery of BMP-2-producing cells: a regional gene therapy approach to bone regeneration. Biomaterials. 22:(11):2001;1271-1277
53. Krebsbach P.H., Gu K., Franceschi R.T., Rutherford R.B. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum Gene Ther. 11:(8):2000;1201-1210
54. Musgrave D.S., Pruchnic R., Wright V., Bosch P., Ghivizzani S.C., Robbins P.D., et al. The effect of bone morphogenetic protein-2 expression on the early fate of skeletal muscle-derived cells. Bone. 28:(5):2001;499-506
55. Lou J., Xu F., Merkel K., Manske P. Gene therapy: adenovirus-mediated human bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo. J Orthop Res. 17:(1):1999;43-50
56. Musgrave D.S., Bosch P., Lee J.Y., Pelinkovic D., Ghivizzani S.C., Whalen J., et al. Ex vivo gene therapy to produce bone using different cell types. Clin Orthop. (378):2000;290-305
57. Chen Y., Cheung K.M., Kung H.F., Leong J.C., Lu W.W., Luk K.D. In vivo new bone formation by direct transfer of adenoviral-mediated bone morphogenetic protein-4 gene. Biochem Biophys Res Commun. 298:(1):2002;121-127
58. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 91:(10):1994;4407-4411
59. Yang Y., Jooss K.U., Su Q., Ertl H.C., Wilson J.M. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:(2):1996;137-144
60. Abe N., Lee Y.P., Sato M., Zhang X., Wu J., Mitani K., et al. Enhancement of bone repair with a helper-dependent adenoviral transfer of bone morphogenetic protein-2. Biochem Biophys Res Commun. 297:(3):2002;523-527
61. Pan R.Y., Xiao X., Chen S.L., Li J., Lin L.C., Wang H.J., et al. Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. J Virol. 73:(4):1999;3410-3417
62. Gao G., Qu G., Burnham M.S., Huang J., Chirmule N., Joshi B., et al. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther. 11:(15):2000;2079- 2091
63. Bonadio J. Tissue engineering via local gene delivery. J Mol Med. 78:(6):2000;303-311
64. Fang J., Zhu Y.Y., Smiley E., Bonadio J., Rouleau J.P., Goldstein S.A., et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci USA. 93:(12):1996;5753-5758
65. Yi A.K., Klinman D.M., Martin T.L., Matson S., Krieg A.M. Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol. 157:(12):1996;5394-5402
66. Jaroszeski M.J., Gilbert R., Nicolau C., Heller R. In vivo gene delivery by electroporation. Adv Drug Deliv Rev. 35:(1):1999;131-137
67. Clackson T. Controlling mammalian gene expression with small molecules. Curr Opin Chem Biol. 1:(2):1997;210-218
68. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 89:(12):1992;5547-5551
69. Corbel S.Y., Rossi F.M. Latest developments and in vivo use of the Tet system: ex vivo and in vivo delivery of tetracycline-regulated genes. Curr Opin Biotechnol. 13:(5):2002;448-452
70. Moutsatsos I.K., Turgeman G., Zhou S., Kurkalli B.G., Pelled G., Tzur L., et al. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther. 3:(4):2001;449-461